X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Tellus’s lead candidate, TT-20, is derived from a class of molecules found in breast milk, which promote the generation of myelin from postnatal neural stem populations.
Lead Product(s): TT-20
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: TT-20
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Perceptive Xontogeny Venture Fund
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 13, 2022
Details:
Tellus’s lead candidate, TT-20, is derived from a class of molecules found in breast milk, which promote oligodendrocyte differentiation in postnatal neural stem cell populations.
Lead Product(s): TT-20
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: TT-20
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Xontogeny, LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing May 12, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
